Amkey Ventures leads $20m Series A1 for for biopharmaceutical company Apexigen

Amkey Ventures has led a $20m Series A round for biopharmaceutical startup Apexigen, which is developing antibody-based drugs for the treatment of life threatening and hard to treat diseases.